Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Route Efficiency Assessment and Review of the Synthesis of β-Nucleosides via N-Glycosylation of Nucleobases

07 August 2020, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Instead of focusing on maximizing glycosylation yield, future syntheses of nucleosides via N-glycosylation should aim to use shorter routes, fewer protecting groups and less chromatography to achieve more efficient and sustainable processes, as this E-factor analysis reveals.

Keywords

Nucleoside
E-factor
yield
solvent
chromatography
glycosylation
sugar

Supplementary materials

Title
Description
Actions
Title
Supporting Info Kaspar 2020 N-Glycosylation
Description
Actions
Title
SI Kaspar 2020 N-Glycosylation
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Now Published

Route efficiency assessment and review of the synthesis of β-nucleosides via N-glycosylation of nucleobases [opens in a new tab]
Felix Kaspar, M. Rhia L. Stone, Peter Neubauer, Anke Kurreck journal article
Green Chemistry , Volume 23, Issue 1
Online publication date: 2021

Version History

Aug 07, 2020 Version 1

Metrics

2,540
393
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.12753413.v1
D O I: 10.26434/chemrxiv.12753413.v1 [opens in a new tab]

Author’s competing interest statement

A. K. is CEO of the biotech company BioNukleo GmbH. F. K. is a scientist at BioNukleo GmbH and P. N. is a member of the advisory board. These affiliations constitute no conflict of interest with the results presented and discussed in this report.

Share